Latest news with #Slusher
Los Angeles Times
3 days ago
- Business
- Los Angeles Times
CBRE Arranges $25.7-Million Sale of Westport Plaza & Square in Costa Mesa
CBRE announced the sale of Westport Plaza & Square, a 39,334-square-foot shopping center along East 17th Street in Costa Mesa, California, to Asana Partners for $25.7 million. CBRE's National Retail Partners-West (NPR-West) team, led by Jimmy Slusher along with Megan Lanni and Shaya Northrup, represented both the seller, Newport Beach-based Space Investment Partners, and the buyer, Asana Partners, in the transaction. Westport Plaza & Square is located at 369 East 17th Street and 1685 Tustin Avenue in Costa Mesa. The property is 97% leased to a mix of popular local tenants, including neighborhood staples Plums Café & Catering, Fleur De Lys, Crumbl Cookies, Common Thread, House of Yogurt, Massimos Pizza, Laser Away and others. 'Westport Plaza & Square enjoys one of the premier retail locations in Orange County. Surrounded by a vibrant mix of national and specialty grocers, upscale dining, stylish boutiques and affluent demographics, the property location serves as its anchor and provides a competitive edge,' said Lanni. Built in 1975 and renovated in 2002 and 2018, the center encompasses 13.73 acres of leased land and benefits from over 535 feet of linear frontage along East 17th Street. Westport Plaza & Square is subject to a long-term ground lease through 2079, with a total remaining term, inclusive of options, of just over 54 years. According to Slusher, 'The sale of Westport Plaza & Square marks a milestone for Costa Mesa's East 17th Street, with the buyer, Asana Partners, becoming the first institutional investor to commit capital along this retail corridor. This acquisition reflects the growing confidence in the area's long-term value and underscores the strategic positioning of the property in the heart of this retail hub.' 'With its compelling neighborhood demographics, the Westport Plaza & Square acquisition aligns with our strategy of targeting well-located, retail assets where we see an opportunity to continue to elevate the shopping and dining experience for the community,' said Bri Baffer, director of investments for Asana Partners. Slusher continued, 'The strong competition to acquire Westport Plaza & Square – from a distinguished pool of well-capitalized investors, including institutional capital – demonstrates investors' preference to own top-tier assets with seasoned, high-performing tenancy, even without a traditional anchor.' Information was sourced from CBRE. Learn more by contacting
Indianapolis Star
27-04-2025
- Sport
- Indianapolis Star
Transfer safety again commits to Barry Odom, this time with Purdue football
Purdue football landed a transfer commitment late Saturday night from a defensive back familiar with first-year coach Barry Odom. Myles Slusher committed to the Boilermakers. He joins the team after sitting out the 2024 season. He played three seasons at Arkansas (2020-22), where Odom was defensive coordinator during his recruitment. Slusher was originally a four-star recruit, No. 172 nationally and the 12th best safety, in 247Sports composite rankings. Slusher then played at Colorado for Deion Sanders, before again entering the transfer portal. He was listed on Alabama A&M's 2025 spring roster. "I'm back," Slusher wrote on social media committing to Purdue. Slusher was listed as a 6-foot, 195-pound safety at Colorado, making six tackles in the Buffaloes' first win under Sanders against TCU, including a game-winning tackle. But he only played four games after suffering an injury. He matched a game-high six tackles against Arizona State that year and finished his Buffs tenure with 17 tackles, 1.5 for loss, one sack and one pass breakup. Need a break? Play the USA TODAY Daily Crossword Puzzle. A native of Broken Arrow, Oklahoma, Slusher started his career at Arkansas. He played in 23 games and his best season was his second in 2021. He had career highs of 50 tackles, four pass breakups, six deflections and two interceptions. His next season he had a career-high 5 tackles for loss and 2 sacks. He also factored into special teams on both kick and punt returns. 'Athletically, there's not a lot of guys that can go from safety to play corner, skillset-wise and how we're playing it. Slush is one of them,' Odom said before Slusher's breakout sophomore season. He moved to nickelback the next season but Odom noted, "he can play any position on the back end." The 23-year-old Slusher has two years of eligibility.
Yahoo
06-03-2025
- Health
- Yahoo
Allosteric Bioscience, Inc. Licenses Sarcopenia (Muscle Loss) Prevention/Treatment Technology from Johns Hopkins University
NEW YORK, March 06, 2025--(BUSINESS WIRE)--Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a serious medical condition involving the loss of muscle mass, quality, and strength and is a significant part of the natural aging process. Sarcopenia can result in reduced quality of life due to falls, bone fractures, and disability. Because approximately 20% of the global population of 8.2 billion people are over 60, there is a global need for improving the aging process, especially preventing the loss of muscle mass and function. The licensed technology was developed by Barbara Slusher, PhD, and colleagues from Johns Hopkins University School of Medicine. Dr. Slusher is a professor of neurology (primary), pharmacology and molecular sciences, psychiatry, neuroscience, medicine and oncology and the Director of Johns Hopkins Drug Discovery. Dr. Slusher has published over 300 scientific articles and reviews and is the inventor of over 100 patents and patent applications. Prior to joining Johns Hopkins University School of Medicine, she spent 18 years in the pharmaceutical industry, including several years at the level of senior vice president of research and translational development, and contributed to the development of multiple FDA-approved drugs. She is the co-founder of several companies and is on the advisory board of multiple pharmaceutical companies. The licensed technology covers the use of inhibitors of an enzyme termed GCPII (glutamate carboxypeptidase II) for the treatment of sarcopenia. The levels of GCPII increase with aging and its overactivation can cause loss of muscle mass and function. Initial studies of the licensed technology in an animal model show that treatment of mice with the licensed technology results in the preservation of muscle mass and function and inhibition of muscle wasting. Prevention of muscle loss could play a significant role in improving and optimizing aging and longevity. Sarcopenia is also a major side effect of weight loss drugs and the licensed technology has the potential of being used with these drugs to prevent this serious side effect. The global market for anti-aging products is estimated to increase from $73 billion in 2024 to $140 billion by 2034 and the anti-obesity drug market size is estimated to rise from $16 billion in 2024 to $105 billion by 2030. "The licensed technology has the potential for significantly improving the aging process and enhancing the utility of weight-reducing treatments which address the global crisis of obesity," said Dr. Arthur P. Bollon, President and Co-Founder of Allosteric Bioscience, Inc. "We are very excited to be working with Dr. Barbara Slusher and her team on this critical program." "At Johns Hopkins Drug Discovery, our mission is to discover innovative drugs with significant medical benefits and to collaborate with commercial partners to bring promising therapeutics to patients," said Dr. Slusher. "We are thrilled to join forces with Allosteric on this groundbreaking sarcopenia project." Allosteric Bioscience, Inc. is a biomedical company focused on optimizing the aging process and extending longevity. The company has a unique strategy for delineating the critical molecular components of the aging/longevity complex and creating and utilizing modulators that can regulate this aging/longevity process. ABI is utilizing quantum computing and advanced AI coupled with biomedical sciences such as genetics, systems biology, and genomics for making modulators of the aging/longevity complex. ABI is also actively involved in licensing created modulators which can complement its internal program for regulating critical aging and longevity targets and processes to optimize both lifespan and health-span. Forward Looking Statement The information contained in this communication is for information purposes only and may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. We use words such as "expects", "anticipates", "believes", "estimates", the negative of these terms and similar expressions to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason. This is neither a solicitation of investment nor an offer to sell and/or buy securities. References herein to "the Company," "we", "our," "us" and similar words or phrases are references to Allosteric Bioscience, Inc., and/or its subsidiaries, unless the context otherwise requires. View source version on Contacts For further information about ABI please visit its website at or contact Dr. Arthur Bollon, President and Co-Founder, arthurb@ phone 469-585-7613 or Bruce Meyers, Executive Chairman and Co-Founder, bmeyers@ phone 646-391-7957. Sign in to access your portfolio
Los Angeles Times
27-02-2025
- Business
- Los Angeles Times
L.A. 2028 Olympics organizers say they are making significant fundraising progress
Organizers of the 2028 Summer Olympics in Los Angeles say they are on track to reach about $2 billion in secured corporate sponsorships by year's end, moving them significantly closer to the $2.5 billion needed to help pay for the costly sporting event. Their optimism stems from what they describe as increased interest from prospective sponsors in the six months since the wildly popular 2024 Paris Games. 'It would not surprise me if we do three or four [times] the sponsorship deals this year, from a dollar standpoint, than we did all of last year,' said John Slusher, chief executive of LA28's commercial operation. 'So business is just on fire.' In the years since L.A. was selected as a host city, organizers have vowed to generate enough revenue to cover their projected $7-billion budget. Sponsorships would represent a major chunk of that total, with other funds coming from International Olympic Committee contributions, ticket sales and merchandising. The likes of Nike and Delta signed major deals early on but, with the Games still years away and the global economy mired in a pandemic, announced sponsorships were stuck at about $1.5 billion. Closing that gap will be crucial because city and state legislators have agreed to settle any Games debt with hundreds of millions in taxpayer dollars. It helps that Paris created a palpable buzz around the Olympic movement. And that the clock is ticking for L.A., with less than four years to go before a planned opening ceremony at the Coliseum and SoFi Stadium. At a Tuesday meeting with existing sponsors in Hollywood, Slusher said he hopes to announce several new deals soon. The former Nike executive, who joined LA28 late last year, stopped short of making specific promises. 'Things could turn the other direction too,' he said. 'So I think we'll know a lot more in three months.'
